Skip to main navigation menu Skip to main content Skip to site footer

Vol. 11 No. 04 (2024)
International Multidisciplinary Journal for Research & Development (IMJRD)

Articles

ANTICOAGULATION: APPROPRIATE OPTION IN HYPERCOAGULABLE STATES

Published 2024-04-07

  • Kuchkarov B.O.

Kuchkarov B.O.
Assistant of the department of “Internal medicine” Andijon State Medical Institute Uzbekistan,Andijon

Abstract

Hypercoagulability or thrombophilia is the increased tendency of blood to thrombose. A normal and healthy response to bleeding for maintaining hemostasis involves the formation of a stable clot, and the process is called coagulation. Hypercoagulability describes the pathologic state of exaggerated coagulation or coagulation in the absence of bleeding. Arterial thrombosis, such as in myocardial infarction and stroke, is different from venous thromboses, such as deep venous thrombosis (DVT) and pulmonary embolism (PE). This activity reviews the cause and presentation of hypercoagulability and highlights the role of the interprofessional team in its management.

Keywords

Hypercoagulability, DVT, PE, direct thrombin inhibitors, heparin, warfarin, INR, bivaluridin.

DOWNLOAD PDF CERTIFICATE

References

  1. Di Nisio M, Middeldorp S, Büller HR. Direct thrombin inhibitors. N Engl J Med 2005; 353:1028.
  2. Rydel TJ, Ravichandran KG, Tulinsky A, et al. The structure of a complex of recombinant hirudin and human alpha-thrombin. Science 1990; 249:277.
  3. Grütter MG, Priestle JP, Rahuel J, et al. Crystal structure of the thrombin-hirudin complex: a novel mode of serine protease inhibition. EMBO J 1990; 9:2361.
  4. Hirsh J, Weitz JI. New antithrombotic agents. Lancet 1999; 353:1431.
  5. Hall SW, Nagashima M, Zhao L, et al. Thrombin interacts with thrombomodulin, protein C, and thrombin-activatable fibrinolysis inhibitor via specific and distinct domains. J Biol Chem 1999; 274:25510.
  6. Sheehan JP, Sadler JE. Molecular mapping of the heparin-binding exosite of thrombin. Proc Natl Acad Sci U S A 1994; 91:5518.
  7. Weitz JI, Hudoba M, Massel D, et al. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990; 86:385.
  8. Turpie AG. New oral anticoagulants in atrial fibrillation. Eur Heart J 2008; 29:155.
  9. Berry CN, Girardot C, Lecoffre C, Lunven C. Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: comparison with heparin and recombinant Hirudin. Thromb Haemost 1994; 72:381.
  10. Lefkovits J, Topol EJ. Direct thrombin inhibitors in cardiovascular medicine. Circulation 1994; 90:1522.
  11. Taxirovich, A. S. (2023). The Main Etiological Factors, Methods of Prevention and Treatment of Meningitis. Inter-national Journal of Scientific Trends, 2(2), 141-148.
  12. Bello D, Herrick CA, Smith TJ, et al. Skin exposure to isocyanates: reasons for concern. Environ Health Perspect 2007; 115:328.
  13. Redlich CA, Herrick CA. Lung/skin connections in occupational lung disease. Curr Opin Allergy Clin Immunol 2008; 8:115.
  14. Kusaka Y. [Asthma due to hard alloy dusts--a case of allergic bronchial asthma and contact dermatitis due to metallic cobalt]. Nihon Kyobu Shikkan Gakkai Zasshi 1983; 21:582.
  15. Lynde CB, Obadia M, Liss GM, et al. Cutaneous and respiratory symptoms among professional cleaners. Occup Med (Lond) 2009; 59:249.

Downloads

Download data is not yet available.